The nation of Zimbabwe has turned down a major US healthcare agreement worth 367 million US dollars (£272m) over five years because of the United States' request for sensitive biological samples.
This rejection was revealed after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman later explained that the US was seeking genetic material for research and profit while was not willing to share the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for more dialogue to find a deal suitable to all parties so the nation's vital HIV programme can proceed.
Wider Implications
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a high court halted a related deal with the US after legal challenges were raised about the safety of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
According to reports, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for medical research with no certainty that the final treatments would be available to our population if a future pandemic arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems already established through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This framework is designed to guarantee that when a nation contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how future co-operation could be designed in a way that honours the independence and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but recommended that talks need to persist since a large portion of the nation's Aids initiatives depended on international support.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," it added.
This impasse underscores the ongoing challenges between receiving crucial foreign assistance and protecting a country's data in an ever more data-driven world.